Loading
A phase 1/2 trial of JIN-A02 in non-small-cell lung cancer, run by J Ints Bio, now recruiting.
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC is a phase 1/2 interventional study registered as NCT05394831 by J Ints Bio, with 150 participants planned, started 2023-07-30 and due to reach its primary completion in 2026-09-30. Interventions recorded: JIN-A02.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.